A Phase 3 interventional study of V503 in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in China. Open to female participants aged 9 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 16 in phase 3, and was the 10th registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Indiana University · Sites in Kenya
Ages 9–49 · Women only · Healthy volunteers
Western Institute for Veterans Research · Sites in United States
Ages 18+
Talia Sainz Costa · Sites in Spain
Ages 9–18 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 9 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 17 · Phase 4 10
First in 2009; this study’s year is marked. 2 started in 2019.
This study's enrollment of 1,990 is above the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 700 across the 31 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
38 studies in Papillomavirus Infections by Merck & Co., Inc: 1 open now, 7 under way, 6 of them phase 3. Of 30 finished, 26 (87%) have results posted.
Among the 38 studies in Papillomavirus Infections by Merck & Co., Inc, this one is the 8th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2019, is one of 26 in phase 3, and was the 30th registered.
Merck & Co., Inc’s Papillomavirus Infections studies by the year they started, since 2000.
3 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, from their registry updates:
Among Merck & Co., Inc’s 38 in Papillomavirus Infections:
This tab as a report to print or save as PDF → With an account.
This study investigates the immunogenicity and safety of the 9vHPV vaccine in healthy Chinese females 9 to 45 years of age. The study consists of Stage I (Day 1 to Month 7) and Stage II (post Month 7 to Month 60). Stage II will report the long-term immunogenicity and safety in the 9-19 year-old age group only. The dual-primary hypotheses of Stage I are that 9vHPV vaccine induces non-inferior immune responses in females 9 to 19 years of age who are seronegative at Day 1 to the relevant HPV type compared to females 20 to 26 years of age who are seronegative at Day 1 to the relevant HPV type, as measured by anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 GMTs at 1 month post Dose 3, and 9vHPV vaccine induces non-inferior immune responses in females 27 to 45 years of age who are seronegative at Day 1 to the relevant HPV type compared to females 20 to 26 years of age who are seronegative at Day 1 to the relevant HPV type, as measured by the seroconversion percentages to each of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 1 month post Dose 3. (Each vaccine component will be analyzed separately.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.
Biological: V503
0.5 mL 9vHPV VLP Vaccine
Stage I: Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age and 20 to 26 Years of Age: Month 7
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as milli Merck units/mL (mMU/mL).
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: Percentage of Participants 27 to 45 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: 1 month post vaccination 3 (Month 7)
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 12
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 24
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 36
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 48
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 60
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 12
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 24
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥65, 37, 79, 85, 46, 26, 21, 30 and 31 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 36
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 48
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 60
Stage II: Immunoglobulin G Luminex Immunoassay (IgG LIA) GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL. Although the same name (mMU/mL) is used for the unit of measurement in both cLIA and IgG LIA, the 'cLIA mMU/mL' and the 'IgG LIA mMU/mL' are actually different units of measurement and cannot be directly compared.
Time frame: Month 12
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 24
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 36
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 48
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: Month 60
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 12
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 24
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 36
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 48
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: Month 60
Stage I: Percentage of Participants 9 to 19 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 15 Years of Age and 20 to 26 Years of Age: Month 7
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL. As pre-specified per protocol, participants 20 to 26 years of age and a subset of participants 9 to 15 years of age were included in the analysis.
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: Percentage of Participants 9 to 15 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively. As pre-specified per protocol, a subset of participants 9 to 15 years of age were included in the analysis.
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 27 to 45 Years of Age: Month 7
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL.
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age: Month 7
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: Percentage of Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Time frame: 1 month post vaccination 3 (Month 7)
Stage I: Percentage of Participants Who Experience at Least 1 Solicited Injection-site Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The participant or the parent/guardian of the participant was to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 8 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, swelling and induration) is reported.
Time frame: Up to 8 days post any vaccination (up to ~Day 192)
Stage I: Percentage of Participants Who Experience at Least 1 Systemic AE
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE is reported.
Time frame: Up to 31 days post any vaccination (Up to ~Month 7)
Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.
Time frame: Day 1 to Month 7
Stage I: Percentage of Participants With Elevated Axillary Temperature (≥37.1 C)
Participant or participant's legally acceptable representative will be asked to record axillary temperature in the evening after each study vaccination and daily, at the same time of day whenever possible, for 8 days after each study vaccination in the VRC. The percentage of participant's who had an axillary temperature ≥37.1°C is reported.
Time frame: Up to 8 days post any vaccination (Up to ~Day 192)
Stage II: Percentage of Participants 9 to 19 Years of Age Who Experience at Least 1 Serious Adverse Event (SAE): Month 7 to Month 60
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.
Time frame: Month 7 to Month 60
| Milestone | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Started | 690 | 650 | 650 |
| Vaccination 1 | 688 | 650 | 650 |
| Vaccination 2 | 683 | 647 | 644 |
| Vaccination 3 | 682 | 635 | 641 |
| 9 to 15 years of age who received at least 1 vaccination | 458 | 0 | 0 |
| Completed | 682 | 635 | 641 |
| Not completed | 8 | 15 | 9 |
| Withdrew: Withdrawal by parent/guardian | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 15 | 9 |
| Milestone | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Started | 682 | 0 | 0 |
| Completed | 645 | 0 | 0 |
| Not completed | 37 | 0 | 0 |
| Withdrew: Withdrawal by subject | 25 | 0 | 0 |
| Withdrew: Lost to follow-up | 12 | 0 | 0 |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | 9 to 19 Years of Age | 20 to 26 Years of Age |
|---|---|---|
| Anti-HPV 6 | 1129.7 (1069.8 to 1193.0) | 861.7 (817.5 to 908.4) |
| Anti-HPV 11 | 926.7 (876.4 to 979.8) | 702.6 (662.7 to 744.9) |
| Anti-HPV 16 | 4972.3 (4696.9 to 5263.9) | 3723.7 (3513.0 to 3946.9) |
| Anti-HPV 18 | 1438.4 (1349.0 to 1533.6) | 1031.6 (964.4 to 1103.6) |
| Anti-HPV 31 | 1161.5 (1093.2 to 1234.2) | 821.9 (770.5 to 876.7) |
| Anti-HPV 33 | 664.3 (626.3 to 704.7) | 497.5 (468.1 to 528.8) |
| Anti-HPV 45 | 442.9 (415.0 to 472.7) | 299.1 (279.8 to 319.9) |
| Anti-HPV 52 | 505.9 (478.4 to 535.0) | 397.8 (374.4 to 422.8) |
| Anti-HPV 58 | 725.3 (685.6 to 767.4) | 535.9 (503.2 to 570.8) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|
| Anti-HPV 6 ≥50 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.3 to 100.0) |
| Anti-HPV 11 ≥29 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.3 to 100.0) |
| Anti-HPV 16 ≥41 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥59 mMU/mL | 99.8 (99.0 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 31 ≥29 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 33 ≥22 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 45 ≥15 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 52 ≥20 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 58 ≥15 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.3 to 100.0) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 420.3 (393.3 to 449.1) |
| Anti-HPV 11 | 341.9 (320.1 to 365.3) |
| Anti-HPV 16 | 1748.7 (1636.7 to 1868.3) |
| Anti-HPV 18 | 472.2 (440.6 to 506.1) |
| Anti-HPV 31 | 403.5 (375.6 to 433.5) |
| Anti-HPV 33 | 237.7 (221.8 to 254.8) |
| Anti-HPV 45 | 144.0 (133.4 to 155.3) |
| Anti-HPV 52 | 187.6 (175.8 to 200.2) |
| Anti-HPV 58 | 272.5 (255.5 to 290.7) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 210.2 (196.4 to 225.0) |
| Anti-HPV 11 | 172.2 (160.7 to 184.5) |
| Anti-HPV 16 | 774.8 (717.2 to 837.1) |
| Anti-HPV 18 | 226.9 (211.8 to 243.0) |
| Anti-HPV 31 | 205.3 (190.4 to 221.4) |
| Anti-HPV 33 | 120.4 (112.2 to 129.2) |
| Anti-HPV 45 | 72.1 (66.8 to 77.8) |
| Anti-HPV 52 | 97.5 (91.3 to 104.2) |
| Anti-HPV 58 | 125.8 (117.0 to 135.3) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 172.6 (161.6 to 184.4) |
| Anti-HPV 11 | 136.5 (127.6 to 146.0) |
| Anti-HPV 16 | 600.5 (554.3 to 650.6) |
| Anti-HPV 18 | 178.0 (166.3 to 190.5) |
| Anti-HPV 31 | 166.9 (154.7 to 180.0) |
| Anti-HPV 33 | 95.1 (88.6 to 102.1) |
| Anti-HPV 45 | 56.9 (52.8 to 61.4) |
| Anti-HPV 52 | 78.1 (73.2 to 83.4) |
| Anti-HPV 58 | 100.9 (93.9 to 108.5) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 170.3 (158.9 to 182.6) |
| Anti-HPV 11 | 123.4 (115.0 to 132.3) |
| Anti-HPV 16 | 612.6 (568.8 to 659.8) |
| Anti-HPV 18 | 151.9 (140.1 to 164.8) |
| Anti-HPV 31 | 165.6 (153.2 to 178.9) |
| Anti-HPV 33 | 87.9 (81.4 to 94.9) |
| Anti-HPV 45 | 53.5 (49.4 to 57.9) |
| Anti-HPV 52 | 75.3 (70.5 to 80.4) |
| Anti-HPV 58 | 97.1 (90.5 to 104.2) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 154.2 (143.5 to 165.6) |
| Anti-HPV 11 | 111.3 (103.5 to 119.6) |
| Anti-HPV 16 | 541.7 (502.0 to 584.5) |
| Anti-HPV 18 | 132.9 (122.5 to 144.1) |
| Anti-HPV 31 | 147.1 (135.9 to 159.2) |
| Anti-HPV 33 | 79.0 (73.1 to 85.3) |
| Anti-HPV 45 | 48.3 (44.5 to 52.4) |
| Anti-HPV 52 | 68.6 (64.1 to 73.3) |
| Anti-HPV 58 | 86.8 (80.6 to 93.4) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥50 mMU/mL | 99.5 (98.6 to 99.9) |
| Anti-HPV 11 ≥29 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 16 ≥41 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥59 mMU/mL | 99.0 (97.9 to 99.6) |
| Anti-HPV 31 ≥29 mMU/mL | 99.4 (98.4 to 99.8) |
| Anti-HPV 33 ≥22 mMU/mL | 99.5 (98.6 to 99.9) |
| Anti-HPV 45 ≥15 mMU/mL | 98.9 (97.8 to 99.6) |
| Anti-HPV 52 ≥20 mMU/mL | 99.7 (98.9 to 100.0) |
| Anti-HPV 58 ≥15 mMU/mL | 100.0 (99.4 to 100.0) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥50 mMU/mL | 96.4 (94.6 to 97.7) |
| Anti-HPV 11 ≥29 mMU/mL | 98.3 (96.9 to 99.1) |
| Anti-HPV 16 ≥41 mMU/mL | 99.1 (98.0 to 99.7) |
| Anti-HPV 18 ≥59 mMU/mL | 95.7 (93.8 to 97.1) |
| Anti-HPV 31 ≥29 mMU/mL | 98.0 (96.6 to 98.9) |
| Anti-HPV 33 ≥22 mMU/mL | 98.0 (96.5 to 98.9) |
| Anti-HPV 45 ≥15 mMU/mL | 96.8 (95.1 to 98.0) |
| Anti-HPV 52 ≥20 mMU/mL | 96.9 (95.3 to 98.1) |
| Anti-HPV 58 ≥15 mMU/mL | 98.0 (96.6 to 98.9) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥65, 37, 79, 85, 46, 26, 21, 30 and 31 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥65 mMU/mL | 87.3 (84.5 to 89.9) |
| Anti-HPV 11 ≥37 mMU/mL | 94.5 (92.4 to 96.1) |
| Anti-HPV 16 ≥79 mMU/mL | 97.0 (95.4 to 98.2) |
| Anti-HPV 18 ≥85 mMU/mL | 80.5 (77.1 to 83.5) |
| Anti-HPV 31 ≥46 mMU/mL | 90.5 (88.0 to 92.7) |
| Anti-HPV 33 ≥26 mMU/mL | 94.8 (92.8 to 96.4) |
| Anti-HPV 45 ≥21 mMU/mL | 84.9 (81.9 to 87.6) |
| Anti-HPV 52 ≥30 mMU/mL | 86.9 (84.0 to 89.4) |
| Anti-HPV 58 ≥31 mMU/mL | 90.2 (87.5 to 92.4) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥34 mMU/mL | 94.2 (92.0 to 95.9) |
| Anti-HPV 11 ≥25 mMU/mL | 95.9 (94.1 to 97.4) |
| Anti-HPV 16 ≥32 mMU/mL | 99.1 (98.0 to 99.7) |
| Anti-HPV 18 ≥26 mMU/mL | 92.3 (89.8 to 94.3) |
| Anti-HPV 31 ≥15 mMU/mL | 98.3 (96.9 to 99.1) |
| Anti-HPV 33 ≥10 mMU/mL | 97.4 (95.8 to 98.5) |
| Anti-HPV 45 ≥10 mMU/mL | 92.7 (90.4 to 94.6) |
| Anti-HPV 52 ≥14 mMU/mL | 96.8 (95.1 to 98.0) |
| Anti-HPV 58 ≥10 mMU/mL | 98.5 (97.3 to 99.3) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥34 mMU/mL | 92.5 (90.2 to 94.5) |
| Anti-HPV 11 ≥25 mMU/mL | 93.5 (91.3 to 95.4) |
| Anti-HPV 16 ≥32 mMU/mL | 98.9 (97.7 to 99.5) |
| Anti-HPV 18 ≥26 mMU/mL | 90.3 (87.6 to 92.5) |
| Anti-HPV 31 ≥15 mMU/mL | 97.6 (96.0 to 98.6) |
| Anti-HPV 33 ≥10 mMU/mL | 96.2 (94.4 to 97.6) |
| Anti-HPV 45 ≥10 mMU/mL | 89.7 (87.0 to 91.9) |
| Anti-HPV 52 ≥14 mMU/mL | 95.3 (93.3 to 96.8) |
| Anti-HPV 58 ≥10 mMU/mL | 97.9 (96.4 to 98.9) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL. Although the same name (mMU/mL) is used for the unit of measurement in both cLIA and IgG LIA, the 'cLIA mMU/mL' and the 'IgG LIA mMU/mL' are actually different units of measurement and cannot be directly compared.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 355.1 (329.4 to 382.7) |
| Anti-HPV 11 | 290.5 (270.1 to 312.4) |
| Anti-HPV 16 | 1505.2 (1405.6 to 1611.9) |
| Anti-HPV 18 | 340.1 (314.5 to 367.8) |
| Anti-HPV 31 | 331.7 (307.2 to 358.2) |
| Anti-HPV 33 | 194.7 (180.6 to 210.0) |
| Anti-HPV 45 | 112.1 (103.3 to 121.7) |
| Anti-HPV 52 | 153.3 (142.7 to 164.8) |
| Anti-HPV 58 | 230.0 (214.6 to 246.4) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 186.3 (172.2 to 201.5) |
| Anti-HPV 11 | 159.0 (147.3 to 171.7) |
| Anti-HPV 16 | 750.8 (695.2 to 810.8) |
| Anti-HPV 18 | 153.6 (140.4 to 168.0) |
| Anti-HPV 31 | 174.8 (161.1 to 189.6) |
| Anti-HPV 33 | 99.1 (91.3 to 107.5) |
| Anti-HPV 45 | 58.4 (53.5 to 63.9) |
| Anti-HPV 52 | 82.6 (76.7 to 89.1) |
| Anti-HPV 58 | 115.2 (106.8 to 124.4) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 143.2 (132.0 to 155.5) |
| Anti-HPV 11 | 121.9 (112.5 to 132.2) |
| Anti-HPV 16 | 566.1 (521.8 to 614.2) |
| Anti-HPV 18 | 112.3 (102.1 to 123.4) |
| Anti-HPV 31 | 137.3 (126.1 to 149.5) |
| Anti-HPV 33 | 75.4 (69.2 to 82.1) |
| Anti-HPV 45 | 44.2 (40.3 to 48.4) |
| Anti-HPV 52 | 65.0 (60.2 to 70.3) |
| Anti-HPV 58 | 90.0 (83.1 to 97.6) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 121.4 (111.9 to 131.8) |
| Anti-HPV 11 | 104.4 (96.3 to 113.2) |
| Anti-HPV 16 | 491.4 (452.7 to 533.4) |
| Anti-HPV 18 | 96.0 (87.2 to 105.7) |
| Anti-HPV 31 | 122.0 (112.0 to 133.0) |
| Anti-HPV 33 | 65.8 (60.4 to 71.8) |
| Anti-HPV 45 | 38.7 (35.4 to 42.4) |
| Anti-HPV 52 | 56.6 (52.3 to 61.3) |
| Anti-HPV 58 | 79.7 (73.5 to 86.5) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 | 106.8 (98.1 to 116.3) |
| Anti-HPV 11 | 91.3 (83.9 to 99.2) |
| Anti-HPV 16 | 433.6 (398.2 to 472.2) |
| Anti-HPV 18 | 81.9 (74.2 to 90.3) |
| Anti-HPV 31 | 106.1 (97.1 to 115.9) |
| Anti-HPV 33 | 58.3 (53.4 to 63.6) |
| Anti-HPV 45 | 33.6 (30.6 to 36.9) |
| Anti-HPV 52 | 49.6 (45.7 to 54.0) |
| Anti-HPV 58 | 70.8 (65.0 to 77.0) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥9 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 11 ≥6 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 16 ≥5 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥5 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 31 ≥3 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 33 ≥4 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 45 ≥3 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 52 ≥5 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 58 ≥5 mMU/mL | 99.8 (99.1 to 100.0) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥9 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 11 ≥6 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 16 ≥5 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥5 mMU/mL | 99.4 (98.4 to 99.8) |
| Anti-HPV 31 ≥3 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 33 ≥4 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 45 ≥3 mMU/mL | 99.1 (98.0 to 99.7) |
| Anti-HPV 52 ≥5 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 58 ≥5 mMU/mL | 99.5 (98.6 to 99.9) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥9 mMU/mL | 99.7 (98.8 to 100.0) |
| Anti-HPV 11 ≥6 mMU/mL | 99.7 (98.8 to 100.0) |
| Anti-HPV 16 ≥5 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥5 mMU/mL | 98.7 (97.4 to 99.4) |
| Anti-HPV 31 ≥3 mMU/mL | 99.8 (99.1 to 100.0) |
| Anti-HPV 33 ≥4 mMU/mL | 99.4 (98.4 to 99.8) |
| Anti-HPV 45 ≥3 mMU/mL | 98.4 (97.1 to 99.2) |
| Anti-HPV 52 ≥5 mMU/mL | 99.2 (98.1 to 99.7) |
| Anti-HPV 58 ≥5 mMU/mL | 99.0 (97.9 to 99.6) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥9 mMU/mL | 99.2 (98.1 to 99.7) |
| Anti-HPV 11 ≥6 mMU/mL | 99.2 (98.1 to 99.7) |
| Anti-HPV 16 ≥5 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥5 mMU/mL | 98.5 (97.2 to 99.3) |
| Anti-HPV 31 ≥3 mMU/mL | 99.5 (98.6 to 99.9) |
| Anti-HPV 33 ≥4 mMU/mL | 98.5 (97.2 to 99.3) |
| Anti-HPV 45 ≥3 mMU/mL | 98.6 (97.3 to 99.3) |
| Anti-HPV 52 ≥5 mMU/mL | 98.7 (97.5 to 99.4) |
| Anti-HPV 58 ≥5 mMU/mL | 99.0 (97.9 to 99.6) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥9 mMU/mL | 99.0 (97.9 to 99.6) |
| Anti-HPV 11 ≥6 mMU/mL | 99.0 (97.9 to 99.6) |
| Anti-HPV 16 ≥5 mMU/mL | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥5 mMU/mL | 97.5 (95.9 to 98.6) |
| Anti-HPV 31 ≥3 mMU/mL | 99.7 (98.8 to 100.0) |
| Anti-HPV 33 ≥4 mMU/mL | 98.2 (96.8 to 99.1) |
| Anti-HPV 45 ≥3 mMU/mL | 97.9 (96.4 to 98.9) |
| Anti-HPV 52 ≥5 mMU/mL | 98.2 (96.8 to 99.1) |
| Anti-HPV 58 ≥5 mMU/mL | 98.7 (97.4 to 99.4) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age | 20 to 26 Years of Age |
|---|---|---|
| Anti-HPV 6 ≥50 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 11 ≥29 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 16 ≥41 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥59 mMU/mL | 100.0 (99.4 to 100.0) | 99.8 (99.0 to 100.0) |
| Anti-HPV 31 ≥29 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 33 ≥22 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 45 ≥15 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 52 ≥20 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 58 ≥15 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL. As pre-specified per protocol, participants 20 to 26 years of age and a subset of participants 9 to 15 years of age were included in the analysis.
| mMU/mL | 20 to 26 Years of Age | 9 to 19 Years of Age |
|---|---|---|
| Anti-HPV 6 | 861.7 (817.5 to 908.4) | 1201.1 (1123.6 to 1284.0) |
| Anti-HPV 11 | 702.6 (662.7 to 744.9) | 981.6 (917.5 to 1050.2) |
| Anti-HPV 16 | 3723.7 (3513.0 to 3946.9) | 5279.6 (4943.8 to 5638.3) |
| Anti-HPV 18 | 1031.6 (964.4 to 1103.6) | 1582.4 (1469.4 to 1704.1) |
| Anti-HPV 31 | 821.9 (770.5 to 876.7) | 1253.1 (1167.7 to 1344.9) |
| Anti-HPV 33 | 497.5 (468.1 to 528.8) | 699.6 (653.5 to 748.9) |
| Anti-HPV 45 | 299.1 (279.8 to 319.9) | 490.5 (454.3 to 529.6) |
| Anti-HPV 52 | 397.8 (374.4 to 422.8) | 535.1 (501.4 to 571.1) |
| Anti-HPV 58 | 535.9 (503.2 to 570.8) | 771.5 (721.8 to 824.6) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively. As pre-specified per protocol, a subset of participants 9 to 15 years of age were included in the analysis.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Anti-HPV 6 ≥50 mMU/mL | 100.0 (99.1 to 100.0) |
| Anti-HPV 11 ≥29 mMU/mL | 100.0 (99.1 to 100.0) |
| Anti-HPV 16 ≥41 mMU/mL | 100.0 (99.2 to 100.0) |
| Anti-HPV 18 ≥59 mMU/mL | 100.0 (99.1 to 100.0) |
| Anti-HPV 31 ≥29 mMU/mL | 100.0 (99.2 to 100.0) |
| Anti-HPV 33 ≥22 mMU/mL | 100.0 (99.1 to 100.0) |
| Anti-HPV 45 ≥15 mMU/mL | 100.0 (99.2 to 100.0) |
| Anti-HPV 52 ≥20 mMU/mL | 100.0 (99.1 to 100.0) |
| Anti-HPV 58 ≥15 mMU/mL | 100.0 (99.1 to 100.0) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL.
| mMU/mL | 27 to 45 Years of Age |
|---|---|
| Anti-HPV 6 | 784.1 (738.9 to 832.1) |
| Anti-HPV 11 | 634.7 (596.1 to 675.8) |
| Anti-HPV 16 | 3175.0 (2983.0 to 3379.5) |
| Anti-HPV 18 | 838.9 (783.8 to 897.8) |
| Anti-HPV 31 | 699.9 (658.3 to 744.1) |
| Anti-HPV 33 | 422.7 (396.9 to 450.1) |
| Anti-HPV 45 | 245.1 (229.8 to 261.5) |
| Anti-HPV 52 | 342.1 (322.2 to 363.2) |
| Anti-HPV 58 | 435.2 (408.1 to 464.2) |
Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.
| mMU/mL | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Anti-HPV 6 | 1177.1 (1105.1 to 1253.7) | 835.9 (785.7 to 889.3) | 717.2 (668.3 to 769.8) |
| Anti-HPV 11 | 939.9 (884.2 to 999.1) | 670.6 (628.8 to 715.2) | 566.1 (526.0 to 609.1) |
| Anti-HPV 16 | 4746.8 (4473.9 to 5036.4) | 3435.0 (3232.2 to 3650.5) | 2867.6 (2685.8 to 3061.7) |
| Anti-HPV 18 | 1303.8 (1219.5 to 1393.8) | 910.3 (848.6 to 976.5) | 741.7 (690.6 to 796.5) |
| Anti-HPV 31 | 1082.5 (1016.4 to 1152.9) | 744.2 (695.5 to 796.2) | 630.2 (589.5 to 673.6) |
| Anti-HPV 33 | 647.1 (607.3 to 689.5) | 461.7 (433.0 to 492.4) | 384.5 (359.0 to 411.9) |
| Anti-HPV 45 | 397.9 (371.7 to 425.9) | 260.7 (243.0 to 279.6) | 213.7 (199.6 to 228.8) |
| Anti-HPV 52 | 478.8 (450.7 to 508.8) | 354.7 (332.0 to 379.0) | 278.3 (259.2 to 298.8) |
| Anti-HPV 58 | 698.8 (659.0 to 741.1) | 501.0 (469.4 to 534.8) | 399.3 (373.2 to 427.2) |
The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
| Percentage of Participants | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Anti-HPV 6 ≥9 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.3 to 100.0) |
| Anti-HPV 11 ≥6 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.3 to 100.0) |
| Anti-HPV 16 ≥5 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 18 ≥5 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 31 ≥3 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 33 ≥4 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 45 ≥3 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 52 ≥5 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) |
| Anti-HPV 58 ≥5 mMU/mL | 100.0 (99.4 to 100.0) | 100.0 (99.4 to 100.0) | 100.0 (99.3 to 100.0) |
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The participant or the parent/guardian of the participant was to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 8 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, swelling and induration) is reported.
| Percentage of Participants | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Injection site pain | 39.1 ± 35.4 | 44.5 ± 40.6 | 39.1 ± 35.3 |
| Injection site erythema | 9.3 ± 7.2 | 11.1 ± 8.8 | 7.4 ± 5.5 |
| Injection site swelling | 8.1 ± 6.2 | 8.9 ± 6.8 | 5.4 ± 3.8 |
| Injection site induration | 6.3 ± 4.6 | 8.0 ± 6.0 | 6.0 ± 4.3 |
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE is reported.
| Percentage of Participants | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Stage I: Percentage of Participants Who Experience at Least 1 Systemic AE | 50.9 ± 47.1 | 57.1 ± 53.2 | 43.4 ± 39.5 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.
| Percentage of Participants | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE) | 1.3 (0.6 to 2.5) | 2.6 (1.5 to 4.2) | 2.6 (1.5 to 4.2) |
Participant or participant's legally acceptable representative will be asked to record axillary temperature in the evening after each study vaccination and daily, at the same time of day whenever possible, for 8 days after each study vaccination in the VRC. The percentage of participant's who had an axillary temperature ≥37.1°C is reported.
| Percentage of Participants | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age |
|---|---|---|---|
| ≥37.1°C (98.8°F) and <37.6°C (99.7°F) | 20.8 ± 17.8 | 23.8 ± 20.6 | 11.7 ± 9.3 |
| ≥37.6°C (99.7°F) and <39.1°C (102.4°F) | 2.2 ± 1.2 | 2.0 ± 1.1 | 0.5 ± 0.1 |
| ≥39.1°C (102.4°F) | 0.3 ± 0.0 | 0.2 ± 0.0 | 0.0 ± 0.0 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.
| Percentage of Participants | 9 to 19 Years of Age |
|---|---|
| Stage II: Percentage of Participants 9 to 19 Years of Age Who Experience at Least 1 Serious Adverse Event (SAE): Month 7 to Month 60 | 1.5 |
Collected over Stage I: Day 1 to Month 7; Stage II: Post Month 7 to Month 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage I: 9 to 19 Years of Age | 0/690 (0%) | 9/688 (1.3%) | 411/688 (59.7%) |
| Stage I: 20 to 26 Years of Age | 0/650 (0%) | 17/650 (2.6%) | 424/650 (65.2%) |
| Stage I: 27 to 45 Years of Age | 0/650 (0%) | 17/650 (2.6%) | 346/650 (53.2%) |
| Stage II: 9 to 19 Years of Age | 0/682 (0%) | 10/682 (1.5%) | 0/682 (0%) |
| Event | Stage I: 9 to 19 Years of Age | Stage I: 20 to 26 Years of Age | Stage I: 27 to 45 Years of Age | Stage II: 9 to 19 Years of Age |
|---|---|---|---|---|
| Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/688 | 3/650 | 0/650 | 0/682 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/688 | 0/650 | 2/650 | 0/682 |
| Cervical dysplasiaReproductive system and breast disorders | 0/688 | 0/650 | 2/650 | 0/682 |
| Uterine diverticulumReproductive system and breast disorders | 0/688 | 0/650 | 2/650 | 0/682 |
| Supraventricular tachycardiaCardiac disorders | 0/688 | 1/650 | 0/650 | 1/682 |
| Retinal detachmentEye disorders | 0/688 | 0/650 | 1/650 | 0/682 |
| HaemoperitoneumGastrointestinal disorders | 0/688 | 0/650 | 1/650 | 0/682 |
| Inflammatory bowel diseaseGastrointestinal disorders | 0/688 | 0/650 | 1/650 | 0/682 |
| Tooth impactedGastrointestinal disorders | 0/688 | 1/650 | 0/650 | 0/682 |
| Cholecystitis chronicHepatobiliary disorders | 0/688 | 1/650 | 0/650 | 0/682 |
| Event | Stage I: 9 to 19 Years of Age | Stage I: 20 to 26 Years of Age | Stage I: 27 to 45 Years of Age | Stage II: 9 to 19 Years of Age |
|---|---|---|---|---|
| Injection site painGeneral disorders | 270/688 | 294/650 | 259/650 | 0/682 |
| PyrexiaGeneral disorders | 172/688 | 175/650 | 85/650 | 0/682 |
| Injection site erythemaGeneral disorders | 64/688 | 73/650 | 48/650 | 0/682 |
| Injection site swellingGeneral disorders | 60/688 | 63/650 | 38/650 | 0/682 |
| Injection site indurationGeneral disorders | 46/688 | 58/650 | 45/650 | 0/682 |
| CoughRespiratory, thoracic and mediastinal disorders | 51/688 | 35/650 | 27/650 | 0/682 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 45/688 | 44/650 | 22/650 | 0/682 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 42/688 | 40/650 | 19/650 | 0/682 |
| Age, Continuous(years) | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age | Total |
|---|---|---|---|---|
| Mean | 14.0 ± 3.0 | 23.1 ± 1.7 | 35.5 ± 5.1 | 24.0 ± 9.5 |
| Sex: Female, Male(Participants) | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age | Total |
|---|---|---|---|---|
| Female | 690 | 650 | 650 | 1990 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 690 | 650 | 650 | 1990 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 9 to 19 Years of Age | 20 to 26 Years of Age | 27 to 45 Years of Age | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 690 | 650 | 650 | 1990 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Apr 2019 to primary completion in Feb 2025, 70 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 70 months is above that.
Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent